JP2023533218A5 - - Google Patents

Info

Publication number
JP2023533218A5
JP2023533218A5 JP2022580159A JP2022580159A JP2023533218A5 JP 2023533218 A5 JP2023533218 A5 JP 2023533218A5 JP 2022580159 A JP2022580159 A JP 2022580159A JP 2022580159 A JP2022580159 A JP 2022580159A JP 2023533218 A5 JP2023533218 A5 JP 2023533218A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
cancer
compound according
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038781 external-priority patent/WO2021262910A2/en
Publication of JP2023533218A publication Critical patent/JP2023533218A/ja
Publication of JP2023533218A5 publication Critical patent/JP2023533218A5/ja
Pending legal-status Critical Current

Links

JP2022580159A 2020-06-24 2021-06-23 ツブリシン及びタンパク質-ツブリシンコンジュゲート Pending JP2023533218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043771P 2020-06-24 2020-06-24
US63/043,771 2020-06-24
PCT/US2021/038781 WO2021262910A2 (en) 2020-06-24 2021-06-23 Tubulysins and protein-tubulysin conjugates

Publications (2)

Publication Number Publication Date
JP2023533218A JP2023533218A (ja) 2023-08-02
JP2023533218A5 true JP2023533218A5 (https=) 2024-07-04

Family

ID=76959103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580159A Pending JP2023533218A (ja) 2020-06-24 2021-06-23 ツブリシン及びタンパク質-ツブリシンコンジュゲート

Country Status (15)

Country Link
US (1) US20230069722A1 (https=)
EP (1) EP4171653A2 (https=)
JP (1) JP2023533218A (https=)
KR (1) KR20230028325A (https=)
CN (1) CN115867563B (https=)
AU (1) AU2021296449A1 (https=)
BR (1) BR112022024361A2 (https=)
CA (1) CA3185601A1 (https=)
CL (1) CL2022003715A1 (https=)
CO (1) CO2022019161A2 (https=)
IL (1) IL299254A (https=)
MA (1) MA58646A1 (https=)
MX (1) MX2022015769A (https=)
PH (1) PH12023550032A1 (https=)
WO (1) WO2021262910A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
JP7590328B2 (ja) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス,インコーポレーテッド ツブリシン及びタンパク質-ツブリシンコンジュゲート
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
US20230414775A1 (en) 2021-12-29 2023-12-28 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
CN116747315A (zh) * 2023-06-20 2023-09-15 中国科学院长春应用化学研究所 高dar值的抗体-免疫调节药物偶联物及其制备方法和应用
CN121568720A (zh) 2023-07-10 2026-02-24 瑞泽恩制药公司 抗人类cacng1抗体-药物缀合物及其用途
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス, インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
WO2008138561A1 (en) 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101909441B (zh) * 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
ES2781523T3 (es) * 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
LT2956173T (lt) * 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
EA032203B1 (ru) * 2014-04-11 2019-04-30 МЕДИММЬЮН ЭлЭлСи Производные тубулизина
FI3900742T3 (fi) * 2014-09-11 2024-08-16 Seagen Inc Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
US10077287B2 (en) * 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3411371A1 (en) * 2016-02-01 2018-12-12 Pfizer Inc Tubulysin analogs and methods for their preparation
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CN109069665A (zh) * 2016-05-10 2018-12-21 百时美施贵宝公司 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
MY199468A (en) * 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MX2020004691A (es) * 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
JP7590328B2 (ja) * 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス,インコーポレーテッド ツブリシン及びタンパク質-ツブリシンコンジュゲート
CN114040781A (zh) * 2019-06-24 2022-02-11 杭州多禧生物科技有限公司 Tubulysin衍生物与细胞结合分子偶联物的制剂配方
KR20220148200A (ko) * 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2023533218A5 (https=)
AU2020263231B2 (en) Camptothecin derivatives
CA3093327C (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
JP7617974B2 (ja) シクロデキストリンタンパク質薬物コンジュゲート
JP7798998B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
KR20230008723A (ko) 전하 변이체 링커
JP2023105175A (ja) グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
CN107614488B (zh) 新型亲水连接体和其在配体-药物共轭偶联物上的应用
KR102576550B1 (ko) 벤조다이아제핀 유도체의 선택적인 설폰화
ES2722103T9 (es) Agentes citotóxicos bifuncionales
KR20240015670A (ko) 안트라사이클린 항체 접합체
TW201838657A (zh) 具有自分解肽連接子之類美登素衍生物及其結合物
JP7854462B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
CN119095625A (zh) 抗体-药物偶联物
CN117750982A (zh) 偶联试剂及其偶联物
JP2025539807A5 (https=)
JP7667870B2 (ja) Dna毒性二量体及びその複合体
CA3137125C (en) Camptothecin derivatives
HK40091718A (zh) 电荷可变接头
RU2021134145A (ru) Производные камптотецина
NZ744373B2 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
NZ744373A (en) Maytansinoid derivatives, conjugates thereof, and methods of use